AXSM vs BCRX Stock Comparison
BCRX currently leads AXSM in this stock comparison, with AIQ scores of 59 vs 47. The clearest difference is value.
What is the main difference between AXSM and BCRX?
BCRX leads the current stock comparison as BioCryst Pharmaceuticals, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Axsome Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
BCRX leads
BCRX leads by 12 AIQ points, primarily on Value and Momentum, and the lead has widened from 9 points over 30 sessions. Wall Street currently favors AXSM on target upside.
Stable: 3 of 6 evidence groups support BCRX, and its lead is widening.
Axsome Therapeutics, Inc.
BioCryst Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors BCRX over AXSM, 59 versus 47 as of Nov 15, 2026. BCRX's advantage is driven primarily by stronger value and momentum. BCRX also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors AXSM. 3 of 6 covered evidence groups favor BCRX today, and the comparison is rated Stable on stability: only 3 of 6 covered evidence groups agree. BCRX lead: Strengthening — the AIQ differential moved from 9 to 12 points over 30 sessions.
Compare Axsome Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare AXSM and BCRX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value65 vs 86BCRX +21
- Momentum24 vs 42BCRX +18
- Quality57 vs 64BCRX +7
- Risk Resilience57 vs 55Even
3 of 6 evidence groups favor BCRX. BCRX’s edge is concentrated in value and momentum.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
BCRX's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — AXSM and BCRX both carry a full feed there.
The central trade-off
BCRX (BioCryst Pharmaceuticals, Inc.): the stronger current systematic profile, led by value and momentum.
AXSM (Axsome Therapeutics, Inc.): the counter-case, on fundamentals, analyst expectations — but at materially higher volatility, 53.2% against 45.2%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BCRXBCRX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
AXSMAXSM on combined revenue and EPS growth.
Value
BCRXBCRX on the peer-relative Value factor, by 21 points.
Momentum
BCRXBCRX on the Momentum factor, by 18 points.
Lower downside
BCRXBCRX carries the lower 1-month annualized volatility.
Analyst upside
AXSMAXSM on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors BCRX, analyst targets favor AXSM. That disagreement is the most useful thing on this page.
| Measure | AXSM | BCRX | Note |
|---|---|---|---|
| Implied upside to target | +83.6% | +44.5% | AXSM has more room |
| Target dispersion | +21.9% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 22 | 11 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor BCRX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BCRX | 47 vs 59 |
| Fundamentals | AXSMon balance | revenue growth 18.9% vs -17.4%; EPS growth 74.7% vs -51.6%; TTM ROE -12.2% vs -9.5%; gross margin 93.2% vs 25.3%; operating margin -17.7% vs -30.1% — AXSM takes 4 of 5 decided legs, not all of them |
| Valuation | BCRX | Value 65 vs 86 |
| Technicals | BCRX | Price vs 50-day -17.4% vs -7.6%; vs 200-day -28.1% vs -13.5% |
| Risk Resilience | Even | Risk Resilience 57 vs 55 |
| Analyst expectations | AXSM | Target upside 83.6% vs 44.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AXSM and BCRX and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 12 points. (supports the conclusion holding)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BCRX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13BCRX lead: Strengthening — the AIQ differential moved from 9 to 12 points over 30 sessions.
- Today
- BCRX +12
- 47 vs 59
- 7 sessions ago
- BCRX +15
- 47 vs 62
- 30 sessions ago
- BCRX +9
- 51 vs 60
- 90 sessions ago
- BCRX +10
- 61 vs 71
The lead changed hands once in this window, most recently on May 29 when AXSM moved ahead of BCRX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish / 1 neutral, conflicted
Only AXSM
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
0 bullish / 2 bearish / 2 neutral
Only BCRX
- ADX Trend Weakening — neutral, trend, medium horizon
Both carry 3 more signals that do not separate them: Death Cross Active, ATR Expansion - Breakout Mode, Downtrend Structure Active.
AXSM is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.86%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.91%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1AXSM closes the Value gap — currently 21 points behind, the largest single contributor to BCRX's edge.
- 2AXSM's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3BCRX starts generating bearish momentum or trend signals.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
AXSM leads on balance| Metric | AXSM | BCRX |
|---|---|---|
| Revenue growth (YoY) | 18.9% | -17.4% |
| EPS growth (YoY) | 74.7% | -51.6% |
| Gross margin | 93.2% | 25.3% |
| Operating margin | -17.7% | -30.1% |
| Return on equity (TTM) | -12.2% | -9.5% |
| Debt to equity | 2.07 | -2.08 |
Performance
BCRX leads 5 of 6 windows| Metric | AXSM | BCRX |
|---|---|---|
| 1 week (5 sessions) | 7% | -1% |
| 1 month (20 sessions) | -9.8% | -2.3% |
| 3 months (63 sessions) | -34.5% | -23.4% |
| 6 months (126 sessions) | -37.8% | -15.6% |
| Year to date | -22.4% | -2.4% |
| 1 year (252 sessions) | 0.6% | 6% |
Technicals
BCRX has the stronger structure| Metric | AXSM | BCRX |
|---|---|---|
| RSI (14) | 40.8 | 40.7 |
| ADX (14) | 37.2 | 15.2 |
| Price vs 50-day | -17.4% | -7.6% |
| Price vs 200-day | -28.1% | -13.5% |
| Volatility (1M, annualized) | 53.2% | 45.2% |
Risk
Split| Metric | AXSM | BCRX |
|---|---|---|
| Beta | 0.66 | 0.65 |
| Sharpe ratio | 0.2 | 0.36 |
| Sortino ratio | 0.34 | 0.56 |
| Max drawdown | -49.1% | -32.2% |
| Current drawdown | -44.5% | -31.5% |
| Annualized volatility | 45.8% | 48.1% |
| Value at risk (95%) | -4.1% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AXSM or BCRX?
On the Algovestiq AIQ Score, BCRX is the stronger of the two as of Nov 15, 2026, scoring 59 against AXSM's 47. The edge comes from value and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AXSM or BCRX the better buy right now?
BCRX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 3 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor BCRX over AXSM?
The composite weights Quality, Value, Momentum and Risk Resilience. BCRX leads Value by 21 points; BCRX leads Momentum by 18 points; BCRX leads Quality by 7 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AXSM or BCRX?
Analyst price targets imply +83.6% upside for AXSM and +44.5% for BCRX, so the Street currently favors AXSM. That points the opposite way to the AIQ Score, which favors BCRX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AXSM or BCRX?
BCRX is the better-valued of the two on the peer-relative Value factor. BCRX on the peer-relative Value factor, by 21 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AXSM or BCRX?
AXSM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AXSM or BCRX?
BCRX on the Momentum factor, by 18 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AXSM or BCRX?
BCRX is the more resilient of the two, so the other name carries the higher downside risk. BCRX carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AXSM more profitable than BCRX?
The profitability evidence is mixed: gross margin 93.2% vs 25.3%; operating margin -17.7% vs -30.1%; ttm roe -12.2% vs -9.5%. AXSM leads on two measures and BCRX on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is BCRX's lead over AXSM getting stronger or weaker?
BCRX lead: Strengthening — the AIQ differential moved from 9 to 12 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-05-29, when AXSM moved ahead of BCRX.
What would change the AXSM vs BCRX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AXSM closes the Value gap — currently 21 points behind, the largest single contributor to BCRX's edge; AXSM's Death Cross Active resolves — a bearish trend rule currently active against it; BCRX starts generating bearish momentum or trend signals; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about AXSM and BCRX?
AXSM: 1 bullish / 2 bearish / 1 neutral, conflicted. BCRX: 0 bullish / 2 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AXSM is Death Cross Active (bearish, long horizon). On BCRX it is Death Cross Active (bearish, long horizon).
Compare AXSM and BCRX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.